Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 03 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Bortezomib for Injection. This medication is used to treat certain types of cancer, including multiple myeloma and mantle cell lymphoma. The drug will be manufactured at Zydus Hospira and has a significant market size.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases